
Feature|Articles|April 7, 2026
ACIP Changes Disrupt Vaccine Coverage Pipeline, Raise Cost Concerns
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.
Advertisement
Advertisement
For decades, the CDC Advisory Committee on Immunization Practices (ACIP) served as the linchpin of pediatric vaccine policy, and by extension, the basis on which insurers determined what they would cover. When ACIP recommended a vaccine, coverage followed. That equation is now broken, and the financial fallout will be felt most acutely by families least equipped to absorb it, according to a panel of experts.
Related to this article

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.
Advertisement
Advertisement

